If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Correspondence Address correspondence to: Jill P. Smith, MD, Department of Medicine, Georgetown University, 3800 Reservoir Road, NW, 2 Main, Room 2408, Washington, District of Columbia 20007.
Gastric cancer is the third leading cause of cancer-related mortality worldwide. Despite progress in understanding its development, challenges with treatment remain. Gastrin, a peptide hormone, is trophic for normal gastrointestinal epithelium. Gastrin also has been shown to play an important role in the stimulation of growth of several gastrointestinal cancers including gastric cancer. We sought to review the role of gastrin and its pathway in gastric cancer and its potential as a therapeutic target in the management of gastric cancer. In the normal adult stomach, gastrin is synthesized in the G cells of the antrum; however, gastrin expression also is found in many gastric adenocarcinomas of the stomach corpus. Gastrin’s actions are mediated through the G-protein–coupled receptor cholecystokinin-B (CCK-B) on parietal and enterochromaffin cells of the gastric body. Gastrin blood levels are increased in subjects with type A atrophic gastritis and in those taking high doses of daily proton pump inhibitors for acid reflux disease. In experimental models, proton pump inhibitor–induced hypergastrinemia and infection with Helicobacter pylori increase the risk of gastric cancer. Understanding the gastrin:CCK-B signaling pathway has led to therapeutic strategies to treat gastric cancer by either targeting the CCK-B receptor with small-molecule antagonists or targeting the peptide with immune-based therapies. In this review, we discuss the role of gastrin in gastric adenocarcinoma, and strategies to block its effects to treat those with unresectable gastric cancer.
The gastrointestinal peptide, gastrin, stimulates growth of gastric adenocarcinoma (gastric cancer) through the cholecystokinin-B receptors that are overexpressed in this malignancy. Serum gastrin levels may be increased secondary to chronic administration of proton pump inhibitors, atrophic gastritis, Helicobacter pylori infection, or from de novo gastrin expression from the gastric cancer epithelial cells. Strategies to interrupt the interaction of gastrin at the cholecystokinin-B receptor may provide a novel approach to the treatment of gastric cancer.
Gastric adenocarcinoma (gastric cancer) is a common malignancy and is the world’s second leading cause of cancer mortality worldwide.
Novel therapeutic targets desperately are needed. The meager improvement in the approximately 10% cure rate realized by adjunctive treatments to surgery is unacceptable because more than 50% of patients with localized gastric cancer die as a result of their disease.
The only curative option in the treatment of gastric cancer is surgery, and for metastatic disease conventional chemotherapy has shown only a modest benefit, with an average survival of approximately 10 months.
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
The current standard of care for advanced gastric cancer in the first-line setting remains a combination of a fluoropyrimidine (eg, 5-fluorouracil) and a platinum (eg, cis-platinum)-containing chemotherapeutic agent. Targeted therapy may offer new possibilities for the treatment of gastric cancer. Because human epidermal growth factor receptor 2 (HER2) receptors are found in approximately 20% of gastric cancers, the addition of a HER2-receptor antibody to standard chemotherapy may be beneficial, as shown in the Trastuzumab for Gastric Cancer study, in which trastuzumab (Herceptin; Genentech, South San Francisco, CA) was beneficial in subjects with HER2-positive gastric cancer.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
However, clinical trials studying the value of other targeted therapies, such as with epidermal growth factor receptor (EGFR) or vascular endothelial growth factor, yielded disappointing results.
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Histologic and Molecular Classifications of Gastric Cancer
In the West, most of those with gastric cancer typically present with advanced or metastatic disease, whereas in several Asian countries, gastric cancer usually is identified early and cure rates are higher.
Other regional differences in gastric cancer are readily identifiable; for example, proximal gastric cancers are more prevalent in Europe and the Americas than in Asia.
classification as either diffuse or intestinal-type. The intestinal-type is characterized by chronic Helicobacter pylori infection; is more prevalent in high-incidence areas such as Japan, Korea, and Eastern Europe
; and the more aggressive diffuse type has been associated with genetic variations (single nucleotide polymorphisms) of the prostate stem cell antigen.
The Cancer Genome Atlas (TCGA) Research Network described 4 groups of gastric cancer based on molecular classifications including Epstein–Barr virus, microsatellite instability, genomically stable, and chromosomal instability.
With the TCGA classification, 73% of the genomically stable were the diffuse type histologically according to Lauren’s criteria and systematic differences in distribution were not observed between East Asian and those of Western origin. The Asian Cancer Research Group
further characterized the molecular classification with the incorporation of the tumor protein 53 activity and epithelial-to-mesenchymal transition and found some unique differences compared with the TCGA analysis.
Risk Factors for Gastric Cancer
Factors associated with an increased risk of gastric cancer include nutrition, such as high salt and nitrate intake, a diet low in vitamins A and C, the consumption of large amounts of smoked or cured foods, lack of refrigerated foods, and poor-quality drinking water.
Other risk factors that have been implicated include the following: cigarette smoking, H pylori infection, Epstein–Barr virus, radiation exposure, and prior gastric surgery for benign ulcer disease.
Helicobacter pylori infection synergizes with three inflammation-related genetic variants in the GWASs to increase risk of gastric cancer in a Chinese population.
Genetic risk factors include type A blood group, pernicious anemia, family history of gastric cancer, hereditary nonpolyposis colon cancer, and Li–Fraumeni syndrome.
Most cases of gastric cancer are sporadic, and gastric cancer associated with an inherited syndrome occurs in only a limited number of patients (1%–3%). E-cadherin mutations occur in approximately 25% of families with an autosomal-dominant hereditary form of diffuse gastric cancer.
Gastrin is released from G cells in the stomach antrum during normal physiologic digestion of food and serves as a major stimulator of gastric acid secretion from the stomach parietal cells (Figure 1).
Proton pump inhibitors (PPIs) have been developed to facilitate healing of peptic ulcer disease and gastroesophageal reflux disease. Because this class of medications is very effective in suppressing acid, a consequence of long-term acid suppression can be the increase of serum gastrin levels
resulting from the interruption of the normal feedback mechanisms. One PPI, omeprazole, causes a 2- to 6-fold increase in serum gastrin levels in 80%–100% of patients receiving chronic therapy.
Up to 30% of patients on chronic PPI therapy may have gastrin blood levels greater than 500 ng/L or more than 6-fold greater than the upper limit of normal.
however, levels return to normal after discontinuation. Although raised as a potential issue at the time of their initial approval 25 years ago, the concern regarding PPI-induced hypergastrinemia has not disappeared completely.
Figure 1Physiologic and pathologic role of gastrin. (A) Under physiologic conditions gastrin is released from antrum G cells in response to food, decreased acid, and gastric distension. Gastrin circulates in the peripheral blood and binds to the CCK-B receptors on the parietal and ECL cells of the body. The ECL cells release histamine, which activates the H2 receptors on parietal cells and HCl (H+) is released. The increased H+ feeds back to the D cells of the antrum to release somatostatin to turn off the gastrin release. Gastrin also is responsible for basal growth and renewal of the gastric epithelium. Normal signaling through the CCK-B receptor occurs through the activation of the phospholipase C-β/diacylglycerol/Ca2+/protein kinase C. (B) Increased gastrin levels can result from achlorhydria, chronic use of PPIs, or H pylori infection. Gastric cancer epithelial cells that express CCK-B receptors also produce their own gastrin de novo, which in turn stimulates growth and metastases of gastric cancer by an autocrine mechanism.
One concern in regard to hypergastrinemia and PPIs has been the potential relationship between gastrin and gastric cancer. When gastrin is administered in animal models, there is a marked increase in parietal cell mass and the enterochromaffin-like (ECL) cells of the stomach body.
have been associated with gastric carcinoid tumors arising from the ECL cells. In cell culture, gastrin has been shown to stimulate the growth of human gastric cancer cell lines.
Several reviews and meta-analyses have been performed concerning the association between PPI use and risk for gastrointestinal cancers without confirmatory results.
Gastrin Mediates its Effects Through the Cholecystokinin-B Receptor
Gastrin mediates both its acid-releasing and growth properties on the gastrointestinal tract through a G-protein–coupled receptor called the cholecystokinin (CCK) or CCK-B receptor (CCK-BR).
After interacting with the CCK-BR on parietal or ECL-like cells, downstream signaling occurs through the activation of the phospholipase C–β/diacylglycerol/Ca2+/protein kinase C cascade
The EGFR phosphorylates phosphoinositide 3-kinase, activating PDK1, Protein kinase B (PKB), and mammalian target of rapamycin. The EGFR interacts with adaptor proteins Grb2 and SOS, activating Ras and Raf, followed by phosphorylation of Mitogen-activated protein kinase/ERK and extracellular signal–regulated kinase (ERK). Gastrin also has been shown to mediate its actions by up-regulating phosphorylation of ERK and K-Ras through the Ras-Raf-MEK1/2-ERK1/2 pathway.
The mechanisms involved with gastrin gene activation or gastrin peptide re-expression are unknown, however, several mechanisms have been proposed. EGFR ligands have been shown to induce gastrin gene transcription in a human gastric cancer cell line, through an EGF response element that has been mapped to the gastrin promoter.
The gastrin promoter activation is mediated in part by the Ras–Erk signaling cascade that targets Sp1, a zinc finger transcription factor that is involved in regulating expression of a large number of genes that contribute to the “hallmarks of cancer.”
analyzed 20 resected human gastric cancers and found that all expressed CCK-B receptors and gastrin messenger RNA by real-time reverse-transcription polymerase chain reaction. They confirmed gastrin peptide expression in 16 of 20 gastric cancers by Western blot analysis and immunohistochemistry (IHC). Henwood
examined 279 human gastric cancers and found gastrin peptide expression by IHC in 47.7% and the CCK-B receptor in 56.6%; the CCK-B receptor detection was significantly greater in tumors characterized as intestinal-type by the Lauren
An explanation for these dissimilarities may be related to gastrin’s actions on the stem cells in the antrum compared with the corpus. Through lineage tracing experiments, Hayakawa et al
reported that the CCK-B receptor expression in the stomach antrum is expressed in position 4+ of antral stem cells and responds to progastrin rather than gastrin-17. In the gastric cardia CCK-B receptors are found on position 4+ stem cells, but unlike the antral stem cells these cells respond to the proliferative actions of amidated gastrin-17.
Although many investigators had thought that the mechanism solely due to chronic inflammation induced by H pylori, studies now have shown that H pylori also induces genetic and epigenetic changes that lead to genetic instability in gastric epithelial cells.
recently described strain differences in H pylori in regard to the presence or absence of a 40-kb chromosomal region known as the cag pathogenicity island. Current evidence suggests that the risk of gastric cancer is very low among persons harboring H pylori strains that lack the cag pathogenicity island. A relationship between gastrin and H pylori infections has shown that gastrin messenger RNA is up-regulated by H pylori–cytotoxin–associated protein A.
showed that infection of canine G cells with H pylori increased endogenous gastrin secretion from the G cells by 17%–27%. In addition, patients with asymptomatic H pylori infection were found to have increased gastrin levels by enzyme-linked immunosorbent assay.
both animal and human studies have shown the greater incidence of gastric carcinoids in patients with increased gastrin levels. One possible explanation for the more frequent neuroendocrine tumors over gastric adenocarcinoma in patients with hypergastrinemia may be related to the finding that although the CCK-B receptor is present on parietal cells, it is expressed more abundantly in ECL cells of the stomach.
In addition to responding to the proliferative effects of gastrin, studies also have shown that the parietal cells respond to other trophic factors secreted by the ECL-like cells by a paracrine mechanism including secretion of Reg protein,
Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene.
With more sophisticated technology using lineage tracing, researchers have confirmed the presence of CCK-B receptors on the antrum stem cells that do not respond to gastrin-17.
These studies also help us understand that hypergastrinemia selectively increases the risk of gastric corpus cancers and low gastrin levels may increase the risk for antral cancers. Whether hypergastrinemia enhances the growth of gastric carcinoids more frequently than gastric adenocarcinoma seems irrelevant when the long-term prognosis differs between these 2 lesions, with adenocarcinoma doing more poorly. Clinical investigations in human subjects also have shown that hypergastrinemia adversely affects survival from subjects with stages 2–4 gastric adenocarcinomas.
Therefore, strategies to decrease gastrin levels in subjects with gastric cancers may be useful.
Gastrin-CCK-B Receptor Pathway
Treatment of cancer is improved significantly when a cancer-specific target or cell surface receptor is identified. Because gastrin has been shown to stimulate growth of gastric cancer and other gastrointestinal malignancies, researchers have been studying means to block the ligand:receptor interaction in an attempt to slow or arrest tumor growth. Numerous investigations have been conducted in cell culture and animal models of gastric cancer using small-molecule CCK-B receptor antagonists,
Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.
Clinical trials in human subjects with agents directed to the gastrin:CCK-B–receptor pathway are rare and most studies have investigated agents in other gastrointestinal cancers rather than in gastric cancer, such as gastrazole in pancreatic cancer
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Polyclonal antibody stimulator (PAS), formerly called G17DT and gastrimmune, was developed as an immunogen containing a 9–amino acid epitope derived from the amino-terminal sequence of gastrin-17 conjugated to diphtheria toxoid (Figure 2A). PAS elicits specific and high-affinity antibodies that bind gastrin-17 and gly-gastrin, thus preventing its trophic activity. Unlike tumor-associated antigen-based vaccines, PAS is unique in that it produces neutralizing antibodies to gastrin with peak titers occurring by week 6 and persisting after vaccination for up to 40 weeks. Preclinical studies were performed in several animal models that have CCK-B receptors,
Passive immunization with PAS antibodies raised in rabbits improved survival of severe combined immunodeficiency disease mice bearing gastric cancers compared with diluent-treated controls
A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.
(Figure 2B). To date, 5 open-labeled clinical trials have been conducted using PAS in subjects with gastric cancer in doses ranging from 10 to 500 μg intramuscularly (Table 1).
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
was a dose-finding study and tested 3 doses and analyzed response according to stage of disease. Only 1 study, GC4, evaluated the safety and survival of PAS in combination with standard chemotherapy.
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
The median survival of those with advanced gastric cancer after PAS administration was prolonged significantly (10.8 mo) in subjects who mounted a circulating antibody titer against gastrin (ie, responders) compared with subjects who failed to generate an antibody response (6.2 mo) (ie, nonresponders) (Figure 2C). The only notable PAS-related adverse events when compared with placebo were injection-site reaction and pyrexia.
Figure 2Polyclonal antibody stimulator. (A) Diagram showing the structure of PAS with the gastrin epitope linked to diphtheria toxoid with a peptide spacer. Characteristics include a molecular weight of 84 kilodaltons; an appearance that is clear, colorless, to slightly yellow solution; and a pH of 7.0–7.4. PAS is water-soluble and administered as an intramuscular injection. (B) Treatment of severe combined immunodeficiency disease mice with gastric cancer showed greater survival compared with mice treated with nonimmune antibody. **P = .015.
(C) Human subjects with gastric cancer treated with PAS vaccination that elicit circulating antibody titers (CAT) have a significantly prolonged survival when compared with subjects who do not elicit an antibody response (P < .0001). (Adapted with permission from Ajani JA, Hecht JR, Ho L, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study. Cancer 2006;106:1908–1916).
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Survival from advanced gastric cancer is poor and new strategies are needed for therapy. CCK-B receptors are overexpressed in many gastric cancers and when these receptors are activated by gastrin, the result is tumor proliferation. Furthermore, many gastric cancers also express gastrin, which stimulates cancer growth by an autocrine mechanism. Understanding the mechanisms and receptor-mediated pathways that regulate the growth of gastric cancer is important. Novel therapeutic agents that target the gastrin:CCK-B–receptor pathways are promising and may help improve survival of advanced gastric cancer.
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Helicobacter pylori infection synergizes with three inflammation-related genetic variants in the GWASs to increase risk of gastric cancer in a Chinese population.
Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene.
Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Conflicts of interest These authors disclose the following: Nick Osborne is employed by Cato Research, a company that owns the rights to the polyclonal antibody stimulator; and Jill Smith serves as a consultant to Cato Research. The remaining author discloses no conflicts.
30050-4&id=gr1.jpg){kind=link}
30050-4&id=gr2.jpg){kind=link}